RESPONSE TO REVIEWER'S COMMENTS

Title: Insights on Antioxidants therapeutic strategies in Type 2 Diabetes Mellitus: A narrative review of randomized control trials

Reviewer 1

| S. No. | Reviewer comment | Author response to reviewer comments |
|--------|--|---|
| 1. | I am really grateful to review this manuscript. In my opinion, this manuscript can be published once some revision is done successfully. This study reviewed 17 randomized control trials on antioxidant therapy in type 2 diabetes mellitus patients. I would argue that this is a good start. However, it needs to be noted that the sample sizes of the reviewed trials were smaller than 200 and this would present a severe restriction on the external validity of this study. I would like to suggest the authors to address this issue as a major limitation of this study. | the discussion section of the revised manuscript. |

Reviewer 2

| S. No. | Reviewer comment | Author response to reviewer comments |
|--------|--|--|
| 1. | This paper is reviewing an important and increasing issue. The oxidative stress role in various diseases and disorders, is well known and studied, therefore, the antioxidant supplementations could be used as a potential therapeutic/preventive approach. The paper is generally well- organized, but needs a little work on the English language and phrasing. Page 5 line 7, the abbreviation PARP-1 was mistakenly written as PRAP-1. Page 7, the abbreviation HOMA-IR index was mentioned without explaining what it stands for, then in page 8 it was explained. The authors should explain the abbreviations meaning the first time it is mentioned, in this case, on page 7. | The suggested change on English language and phrasing has been incorporated in the revised manuscript. PRAP-1 is replaced with PARP-1 (Page 5 line 7), in the revised manuscript. The suggested change on use of abbreviations meaning has been done throughout the text in the revised manuscript. |